MUMBAI, India, Aug. 8 -- Intellectual Property India has published a patent application (202517056953 A) filed by Genome & Company, Inc.; and Debiopharm Research & Manufacturing Sa, Gyeonggi, Republic of Korea, on June 13, for 'anti-basal cell adhesion molecule antibody-drug conjugate.'
Inventor(s) include Cha, Mi Young; Yu, Hyunkyung; Kim, Hyunuk; Ha, Youngeun; Park, Kitae; Jeon, Bunam; Kim, Yun Yeon; Marx, Lo; Pantin, Mathilde; Bellocq, Nathalie; and Levy, Frederic.
The application for the patent was published on Aug. 8, under issue no. 32/2025.
According to the abstract released by the Intellectual Property India: "The present disclosure relates to an anti-basal cell adhesion molecule (BCAM) antibody-drug conjugate where the anti-BCAM antibody is conjugated to an antitumor compound via a linker, a pharmaceutical composition comprising the anti-BCAM antibody-drug conjugate, and a method for treating cancer by administering an effective amount of the anti-BCAM antibody-drug conjugate to a subject in need thereof."
The patent application was internationally filed on Nov. 17, 2023, under International application No.PCT/KR2023/018574.
Disclaimer: Curated by HT Syndication.
